Afaaf Liberty to Infant, Newborn
This is a "connection" page, showing publications Afaaf Liberty has written about Infant, Newborn.
Connection Strength
0,156
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
Score: 0,044
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022 09; 9(9):e638-e648.
Score: 0,037
-
A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. 2019 01 24; 10(1):412.
Score: 0,029
-
Childhood adversity increases the risk of onward transmission from perinatal HIV-infected adolescents and youth in South Africa. Child Abuse Negl. 2018 05; 79:98-106.
Score: 0,027
-
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013 Nov 09; 382(9904):1555-63.
Score: 0,020